PARIS (dpa-AFX) - Ipsen (IPSEF.PK) said Monday it has agreed to acquire Kartos Therapeutics for up to $1.75 billion, expanding its hematology pipeline with navtemadlin, an investigational treatment for myelofibrosis, a rare blood cancer.
The deal includes an upfront payment of $450 million, with Kartos shareholders eligible to receive up to $1.3 billion in additional payments tied to regulatory and commercial milestones.
Navtemadlin is being developed in combination with ruxolitinib for intermediate- and high-risk myelofibrosis patients who have an inadequate response to ruxolitinib alone. The drug is currently being evaluated in Phase III POIESIS trial, with top-line results expected in 2027.
Ipsen expects the acquisition to contribute to core operating income from 2029, while having only a limited impact on its 2026 earnings guidance. The transaction is expected to close by the end of the third quarter.
'We are excited by the potential of navtemadlin to define a new treatment paradigm for patients with myelofibrosis who have a suboptimal response to current standard of care, addressing a critical care gap and offering the potential for a new therapeutic option as early as 2028r,' said David Loew, CEO, Ipsen.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
